Study Name: ECZEMA
Therapy Area: Atopic Dermatitis
Reimbursement: Up to £3150 plus reasonable travel expenses
Gender and Age: Male and female aged 18 to 65
MAC Clinical Research is currently conducting a clinical trial to test an investigational drug for eczema, also known as atopic dermatitis. Eczema is one of the most common types of skin diseases and affects up to 10% of adults. Common features of this inflammatory skin disease include itching and dryness. Eczema often relapses, meaning symptoms will improve for a while but then return.
What causes eczema is not yet known, however high levels of a protein called interleukin 22 (IL-22) in the body are believed to play a role in the disease.
The trial drug aims to reduce the symptoms of eczema by decreasing the activity levels of IL-22 in the body. If the trial drug is proven to work, it could be used to treat people with moderate to severe eczema in the future.
The purpose of this trial is to test if the trial drug improves eczema by looking at any changes, and to see how well tolerated it is. During the trial, eligible participants will receive the trial drug or placebo (a substance used as a ‘dummy medication’ which has no active ingredient or drug in it).
The study will last approx. 23 weeks and over that time there will be:
11 x outpatient visits
1 x in-patient stay of up to 2 nights
4 x in-patient stays of 1 night
If you are eligible and you decide to take part, you may be helping the development of a new potential treatment that may help improve the quality of life for many people with eczema.
A full description of the study will be given before you decide to take part, both over the phone and during an appointment at a MAC clinic. This will include you receiving the full patient information sheet (PIS).
* Key Inclusion Criteria:
Male or female 18 to 65
Diagnosis of eczema for at least the past 6 months
BMI 18 – 32 kg/m2
* Key Exclusion Criteria:
History of tanning beds or phototherapy within 6 weeks of starting trial
History of any severe allergic reactions
Active skin conditions other than eczema
Other eligibility criteria will apply. Please contact MAC for more information.
Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.